Antibody Standards Derived from Trans-chrosomic Bovine

Presentation prepared by LCDR Nicholas J Martin, PhD for discussion at CONSISE Laboratory Working Group Meeting-September 3-4, 2013





The views expressed in this presentation are those of the presenter and do not necessarily reflect the official policy or position of the Department of the Navy, Department of Defense, nor the U.S. Government.

Background


- The Naval Medical Research Center (NMRC) has established a cooperative research and development agreement with Sanford Applied Biosciences (SAB) to develop antibody standards and therapeutics for viral diseases
 - SAB developed a large animal (bovine) trans-chrosomic (Tc) platform to produce fully human antibodies
 - These cattle have the entire human immunoglobulin (Ig) heavy (H) and light (L) chain loci
 - Animals are capable of producing 30-60 L of plasma (150-300 g purified human immunoglobulin) each month






Antibody **Diversity** is the key to successfully treating human disease

SANF: RD APPLIED BIOSCIENCES



Vaccination








Results

	Day	H1N1	H3N2	Influenza B
Animal 635	0	ND	ND	ND
Animal 635	30	2560	320	640
Animal 635	52	1810	1280	2560
Animal 2186	0	ND	ND	ND
Animal 2186	30	5120	1280	1280
Animal 2186	52	1810	2560	5120
Animal 635 Purified IG	0	ND	ND	ND
Animal 635 Purified IG	30	2560	160	320
Animal 635 Purified IG	52	3620	2560	2560
Animal 2186 Purified IG	0	ND	ND	ND
Animal 2186 Purified IG	30	5120	640	640
Animal 2186 Purified IG	52	1280	1280	1280





Tc animals generated cross reactive antibodies against flu viruses not in seasonal vaccine







Conclusions

- The HAI results demonstrate the Tc-bovine produced high titers in response to the administered vaccine
 - MN assays were performed for a single time point resulting in 2-day MN titers of >5,000 against A/California/7/2009
- The high HAI and MN results, coupled with the ability of each animal to produce 30 - 60 L plasma/month could be leveraged to generate control plasma in 30-60 days





Future Work

- Additional work is planned to evaluate Ab generation following administration of inactivated virus and virus like particles (VLPs)
 - Leverages NMRC's experience with virus inactivation and SAB's Tc-bovine platform
 - Current/future efforts include evaluating immune responses against the following viruses:
 - Dengue types 1 4
 - MERS-CoV
 - Filovirus VLPs





Nicholas Martin, PhD LCDR MSC USN Viral and Rickettsial Diseases Department Naval Medical Research Center nicholas.martin@med.navy.mil



This work supported by the Global Emerging Infections Surveillance and Response System (GEIS) project P0202_13_NM

I am a military service member. This work was prepared as part of my official duties. Title 17 U.S.C. § 105 provides that 'Copyright under this title is not available for any work of the United States Government.' . Title 17 U.S.C. § 101 defines a U.S. Government work as a work prepared by a military service member or employee of the U.S> Government as part of that person's official duties.